Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (8222)	2/24/1998 8:47:00 PM
From: AgAuUSA	Read Replies (2) \| Respond to of 14328

Keiko, Patents were licensed for HIVI/HIVII antigens by DDI. DDI was acquired along with the licenses in March 1994 by Triby. HIV1 and HIV2 combination tests using the licensed patents are marketed by Triby. These include: SeroCard HIV, SalivaCard HIV, and UniGold HIV. Product development has been initiated for a urine HIV1 and HIV2 diagnostic test. UniGold Patent application dated June 1994. I hope this puts the HIV1 and HIV2 patent issue to rest. Ref: Trinity Bio 1994 Annual Report; Trinity Bio SemiAnnual report dated Aug 31, 1994